Great news people. Vapendavir (BTA798) - The Company no longer...

Great news people.


Vapendavir (BTA798) - The Company no longer plans to independently continue the clinical development of vapendavir in patients with asthma or chronic obstructive pulmonary disease (COPD), but rather intends to seek collaboration, co-development or license arrangements with third parties to advance its clinical development. In March 2012, the Company completed a 300-patient, Phase 2b clinical trial that evaluated the safety and clinical benefit of vapendavir for the treatment of human rhinovirus (HRV) infections in patients with mild to moderate asthma. The trial successfully met its primary endpoint, which was a reduction of cold symptoms based on the Wisconsin Upper Respiratory Symptom Survey (WURSS) severity score.



http://www.marketwatch.com/story/biota-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-end-financial-results-2013-09-18